1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 35,200 | 37,200 | 09:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.10. | DUALITYBIO-B (09606): INSIDE INFORMATION - PROPOSED ISSUE OF RMB SHARES AND LISTING ON THE SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE | 2 | HKEx | ||
| 17.09. | DUALITYBIO-B (09606): 2025 INTERIM REPORT | 8 | HKEx | ||
| 05.09. | DUALITYBIO-B (09606): INSIDE INFORMATION - PRIMARY ENDPOINT MET FOR PHASE III CLINICAL TRIAL OF DB-1303/BNT323 IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE ... | 19 | HKEx | ||
| 26.08. | DUALITYBIO-B (09606): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 8 | HKEx | ||
| 14.08. | DUALITYBIO-B (09606): DATE OF BOARD MEETING | 1 | HKEx | ||
| 22.07. | Duality Biotherapeutics: DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation | 533 | PR Newswire | SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track... ► Artikel lesen | |
| 22.07. | DUALITYBIO-B (09606): VOLUNTARY ANNOUNCEMENT - KEY PRODUCT DB-1310 GRANTED U.S. FDA FAST TRACK DESIGNATION | 2 | HKEx | ||
| 09.07. | Duality Biotherapeutics: First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 | 433 | PR Newswire | SHANGHAI, July 9, 2025 /PRNewswire/ -- Duality Biotherapeutics' ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing... ► Artikel lesen | |
| DUALITY BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 20.06. | DUALITYBIO-B (09606): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 20, 2025 | - | HKEx | ||
| 10.06. | DUALITYBIO-B (09606): ANNOUNCEMENT MADE PURSUANT TO RULE 13.10 OF THE LISTING RULES | 1 | HKEx | ||
| 05.06. | Duality Biologics: Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting | 601 | PR Newswire | SHANGHAI and CHICAGO, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the preliminary... ► Artikel lesen | |
| 28.05. | DUALITYBIO-B (09606): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 20, 2025 | - | HKEx | ||
| 28.05. | DUALITYBIO-B (09606): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 28.05. | DUALITYBIO-B (09606): (1) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES; (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (INCLUDING ... | 1 | HKEx | ||
| 23.05. | Duality Biotherapeutics: FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 | 190 | PR Newswire | Phase 1/2 first-in-human clinical study planned this year
SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606)... ► Artikel lesen | |
| 06.05. | XFRA NEW INSTRUMENTS AVAILABLE ON 06.05.2025 | 728 | Xetra Newsboard | The following instruments on XETRA do have their first trading 06.05.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 06.05.2025
Aktien
1 KYG2929M1087 Duality Biotherapeutics... ► Artikel lesen | |
| 15.04. | Irrer Börsengang: BioNTech-Partner DualityBio explodiert am ersten Handelstag | 3.697 | Der Aktionär | Die Börse in Hongkong ist seit dem heutigen Mittwoch um ein Biotech-Unternehmen reicher. Duality Biotherapeutics (DualityBio) hat einen furiosen Start auf das Parkett gezaubert - nicht zuletzt dank... ► Artikel lesen | |
| 07.04. | Duality Biotherapeutics: Duality Bio Appoints Hua Mu as Global Chief Medical Officer | 455 | PR Newswire | SHANGHAI, April 7, 2025 /PRNewswire/ -- DualityBio announced today that Dr. Hua Mu has joined the company as Global Chief Medical Officer (CMO). In this role, Dr. Mu will oversee the strategic... ► Artikel lesen | |
| 07.01. | Duality Biotherapeutics: Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate | 349 | PR Newswire | Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing and commercialization of potential best-in-class EGFR/HER3 antibody-drug conjugate
EGFR... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,05 | +0,06 % | Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson? | Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert Vidac Pharma mehr und mehr... ► Artikel lesen | |
| MODERNA | 20,115 | -3,43 % | Biologische Fertigung im Fokus - wie NurExone, Moderna und Lonza von der Industrialisierung regenerativer Therapien profitieren könnten | ||
| PALATIN TECHNOLOGIES | 20,620 | +43,29 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,502 | +3,72 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Conversion | Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,404 | +0,89 % | CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald | ||
| NUVALENT | 105,88 | -1,97 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 70,56 | -0,13 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| QIAGEN | 40,380 | +2,38 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,170 | +8,45 % | Is Recursion Pharmaceuticals a Meme Stock? | ||
| JANUX THERAPEUTICS | 28,800 | +0,73 % | Wolfe Research initiates Janux Therapeutics stock with Peerperform rating | ||
| PRAXIS PRECISION MEDICINES | 169,78 | +3,33 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
| COGENT BIOSCIENCES | 36,770 | +5,97 % | COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know | ||
| OLEMA PHARMACEUTICALS | 23,190 | +5,36 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| IMMUNOVANT | 22,580 | -0,92 % | Immunovant, Inc. - 8-K, Current Report | ||
| ARCUTIS BIOTHERAPEUTICS | 29,460 | +7,89 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen |
DUALITY BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 35,600 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DUALITY BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.